GSK Jumps Into Growing China R&D Space
This article was originally published in The Pink Sheet Daily
Executive Summary
Shanghai-based center will focus on Alzheimer’s, multiple sclerosis and Parkinson’s.
You may also be interested in...
India Highlights "Public Interest" To Reign In Prices For Non-Scheduled Drugs
India's National Pharmaceutical Pricing Authority has imposed a 15-day deadline on 11 drug manufacturers to rein in costs of certain drugs, citing the "public interest" of lower prices for consumers
India Highlights "Public Interest" To Reign In Prices For Non-Scheduled Drugs
Dr. Reddy's, GSK, Ranbaxy and UCB among manufacturers that could see prices reduced under government order that reflects issues raised in Gleevec patent dispute.
India Highlights "Public Interest" To Reign In Prices For Non-Scheduled Drugs
Dr. Reddy's, GSK, Ranbaxy and UCB among manufacturers that could see prices reduced under government order that reflects issues raised in Gleevec patent dispute.